CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV

Table 1 Baseline Characteristics of CHC, GT1 Patients

Variables	Overall	NR (22)^a	non-NR (38)^a	P value
Age (years)	58.23 ± 9.19	55.6 ± 9.2	59.8 ± 9.0	0.090
Male (%)	55.0	50.0	57.9	0.599
BMI (Kg/m²)	25.44 ± 3.22	25.5 ± 3.7	25.4 ± 2.9	0.865
AST (U/L)	80.85 ± 40.27	91 ± 48	75 ± 34	0.118
ALT (U/L)	105.63 ± 59.86	108 ± 53	104 ± 64	0.797
HCV RNA (log₁₀ IU/ml)	3.38(5.17)^b	2.48(4.74)^b	3.72(5.66)^b	0.591
Diabetes Mellitus (%)	25.0	13.6	31.6	0.215
IL28B (CC %)	75.0	50.0	89.5	0.001
Liver cirrhosis (%)	28.3	45.5	18.4	0.038

^anumber of patients shown in parentheses
^bmedian (IQR) shown in parentheses
Data are shown as mean ± standard deviation. Statistic analysis was done by Mann-Whitney test for comparison. Significant P values are shown in bold. AST, aspartate aminotransferase; ALT, alanine aminotransferase; HCV, hepatitis C virus; IL28B, Interleukin-28B

ISSN: 1471-230X